^
    BIOMARKER:

    PD-L1 overexpression

    i
    Other names: PD-L1, CD274, HPD-L1, PD-L1, B7H1, PDL1, Programmed death ligand 1, B7-H1, B7-H, PDCD1L1, PDCD1LG1, PDCD1 Ligand 1, B7 homolog 1, CD274 Antigen, Programmed cell death 1 ligand 1, CD274 molecule
    Contact us to learn more about our Premium Content:
    News alerts, weekly reports and conference planners
    Entrez ID:
    29126
    Related biomarkers:
    Expression
    Mutation
    CNA
    Others
    PD-L1 overexpression
    Non Small Cell Lung Cancer
    sintilimab
    Sensitive
    :
    C3
    BMC Cancer - 3 weeks - (New C3)
    PD-L1 overexpression
    Non Small Cell Lung Cancer
    cemiplimab
    Sensitive
    :
    A1
    PD-L1 overexpression
    Non Small Cell Lung Cancer
    atezolizumab
    Sensitive
    :
    A1
    PD-L1 overexpression
    Urothelial Cancer
    tislelizumab
    Sensitive
    :
    A1
    PD-L1 overexpression
    Non Small Cell Lung Cancer
    pembrolizumab
    Sensitive
    :
    A2
    PD-L1 overexpression
    Lung Non-Squamous Non-Small Cell Cancer
    pembrolizumab
    Sensitive
    :
    A2
    PD-L1 overexpression
    Non Small Cell Lung Cancer
    bevacizumab + atezolizumab
    Sensitive
    :
    A2
    PD-L1 overexpression
    Non Small Cell Lung Cancer
    bevacizumab
    Sensitive
    :
    A2
    PD-L1 overexpression
    Lung Non-Small Cell Squamous Cancer
    atezolizumab
    Sensitive
    :
    A2
    PD-L1 overexpression
    Lung Non-Small Cell Squamous Cancer
    pembrolizumab
    Sensitive
    :
    A2
    PD-L1 overexpression
    Lung Non-Small Cell Squamous Cancer
    nivolumab + ipilimumab
    Sensitive
    :
    A2
    PD-L1 overexpression
    Lung Non-Small Cell Squamous Cancer
    cemiplimab
    Sensitive
    :
    A2
    PD-L1 overexpression
    Non Small Cell Lung Cancer
    atezolizumab + RG6058
    Sensitive
    :
    B
    PD-L1 overexpression
    Non Small Cell Lung Cancer
    carboplatin + albumin-bound paclitaxel
    Sensitive
    :
    B
    PD-L1 overexpression
    Non Small Cell Lung Cancer
    carboplatin + gemcitabine
    Sensitive
    :
    B
    PD-L1 overexpression
    Non Small Cell Lung Cancer
    cisplatin + albumin-bound paclitaxel
    Sensitive
    :
    B
    PD-L1 overexpression
    Non Small Cell Lung Cancer
    GC
    Sensitive
    :
    B
    PD-L1 overexpression
    Non Small Cell Lung Cancer
    carboplatin + pemetrexed
    Sensitive
    :
    B
    PD-L1 overexpression
    Non Small Cell Lung Cancer
    cisplatin + pemetrexed
    Sensitive
    :
    B
    PD-L1 overexpression
    Gastroesophageal Cancer
    PD1 inhibitor
    Sensitive
    :
    B
    PD-L1 overexpression
    Gastroesophageal Cancer
    PD-L1 inhibitor
    Sensitive
    :
    B
    PD-L1 overexpression
    Triple Negative Breast Cancer
    pembrolizumab
    Sensitive
    :
    B
    PD-L1 overexpression
    Non Small Cell Lung Cancer
    tislelizumab
    Sensitive
    :
    B
    PD-L1 overexpression
    Urothelial Cancer
    durvalumab
    Sensitive
    :
    B
    PD-L1 overexpression
    Non Small Cell Lung Cancer
    nivolumab
    Sensitive
    :
    B
    PD-L1 overexpression
    Non Small Cell Lung Cancer
    avelumab
    Sensitive
    :
    B
    PD-L1 overexpression
    Squamous Cell Carcinoma of Head and Neck
    durvalumab
    Sensitive
    :
    B
    PD-L1 overexpression
    Esophageal Squamous Cell Carcinoma
    pembrolizumab
    Sensitive
    :
    B
    PD-L1 overexpression
    Gastric Cancer
    pembrolizumab
    Sensitive
    :
    B
    PD-L1 overexpression
    Gastroesophageal Junction Adenocarcinoma
    pembrolizumab
    Sensitive
    :
    B
    PD-L1 overexpression
    Prostate Cancer
    atezolizumab + enzalutamide capsule
    Sensitive
    :
    B
    PD-L1 overexpression
    Esophageal Adenocarcinoma
    nivolumab
    Sensitive
    :
    B
    PD-L1 overexpression
    Gastroesophageal Junction Adenocarcinoma
    nivolumab
    Sensitive
    :
    B